Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease

Andican G. , Konukoglu D. , Bozluolcay M. , Bayulkem K., Firtiina S., Burcak G.

Acta Neurologica Belgica, cilt.112, sa.2, ss.155-159, 2012 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 112 Konu: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s13760-012-0015-3
  • Dergi Adı: Acta Neurologica Belgica
  • Sayfa Sayıları: ss.155-159


Parkinson's disease (PD) is the most common neurodegenerative disorder after alzheimer's disease. Neuroinflammation and oxidative damage are implicated to be responsible for the pathogenesis of neurodegenerative diseases. However, there are a few studies showing the changes in the biomarkers for neuroinflammation and oxidative damage in neurodegenerative diseases. In our study we aimed to examine the role of the molecules that are involved in oxidative stress and inflammation in PD patients taking l-dopa treatment. Oxidized-LDL (ox-LDL), high-sensitivity C-reactive protein (hs-CRP) and the soluble intracellular adhesion molecule (ICAM) were chosen as biomarkers for systemic inflammation and oxidative damage. The patients were classified according to the Hoehn-Yahr staging system. Forty-five idiopathic l-dopa-given PD patients and 25 age-matched healthy controls were examined. Plasma ox-LDL and ICAM levels were significantly higher in PD patients when compared with controls (p < 0. 001 and p < 0. 05, respectively). PD patients at all stages had significantly higher plasma ox-LDL levels than controls (p < 0. 001). Plasma ICAM levels at stage 1 and 2 and CRP levels at stage 2 patients were significantly higher than controls (p < 0. 05, p < 0. 05, and p < 0. 01, respectively). We insist that further studies have to be conducted to establish neuroinflammation and oxidative damage in PD. Establishing the roles of these pathological processes in PD might be the key to effective therapy at an early stage by antioxidants and/or anti-inflammatory drugs. © 2012 Belgian Neurological Society.